Shanghai BDgene Technology Co., Ltd.

CRISPR-Cas Clinical Trial Update
Nov. 17, 2020

We have added 4 new CRISPR-Cas trials to our overview of current clinical trials involving gene editing.

Shanghai BDgene Technology Co., Ltd.

Transfusion-dependent Beta-Thalassemia, TDT, (NCT05015920)
Sponsors:
Shanghai BDgene Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
Primary Open Angle Glaucoma, POAG, (NCT06465537)
Sponsors:
Shanghai BDgene Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
Herpes Simplex Virus Type I Stromal Keratitis, (NCT06474442)
Sponsors:
Shanghai BDgene Co., Ltd.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Herpes Simplex Virus Type I Stromal Keratitis, (NCT06474416)
Sponsors:
Shanghai BDgene Co., Ltd.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Herpes Simplex Virus Refractory Keratitis, (NCT04560790)
Sponsors:
Shanghai BDgene Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine